Hyo Jung An1,2,3, Dae Hyun Song1,2,3, Yu-Min Kim3, Hyen Chul Jo4,5, Jong Chul Baek3,4,5, Ji Eun Park6,4,5. 1. Department of Pathology, Gyeongsang National University Changwon Hospital, Changwon, Republic of Korea. 2. Department of Pathology, Gyeongsang National University School of Medicine, Jinju, Republic of Korea. 3. Institute of Health Science, Gyeongsang National University, Jinju, Republic of Korea. 4. Department of Obstetrics and Gynecology, Gyeongsang National University School of Medicine, Jinju, Republic of Korea. 5. Department of Obstetrics and Gynecology, Gyeongsang National University Changwon Hospital, Changwon, Republic of Korea. 6. Institute of Health Science, Gyeongsang National University, Jinju, Republic of Korea; obgy@gnu.ac.kr.
Abstract
BACKGROUND/AIM: The majority of patients with early-stage endometrial cancer (EC) have a good prognosis, but recurrence does occur despite diagnosis at an early stage. There is a growing need for early diagnosis of EC and novel treatment options. MATERIALS AND METHODS: Human epidermal growth factor receptor 2 (HER2) and vascular endothelial growth factor receptor 2 (VEGFR) expression in microarrays of patient EC tissue was examined in association with clinicopathological data. HER2 and VEGFR2 expression in Ishikawa cells and differences in migration and proliferation of cells with HER2-knockdown were evaluated. RESULTS: Higher expression of VEGFR2 was associated with lower International Federation of Obstetrics and Gynecology grades (p=0.044). The positive correlation between HER2 and VEFR2 expression was statistically significant in T1 stage (p=0.002) and International Federation of Obstetrics and Gynecology grade 1 tumors (p=0.004). Wound-healing assays revealed that HER2 loss in Ishikawa cells reduced confluence compared to that of control cells. CONCLUSION: The association of VEGFR2 and HER2 expression in early EC was elucidated. This study shows that the measurement of VEGFR2 expression may be useful in the preoperative assessment of EC and suggests the possibility of anti-HER2 therapy for EC. Copyright
BACKGROUND/AIM: The majority of patients with early-stage endometrial cancer (EC) have a good prognosis, but recurrence does occur despite diagnosis at an early stage. There is a growing need for early diagnosis of EC and novel treatment options. MATERIALS AND METHODS: Human epidermal growth factor receptor 2 (HER2) and vascular endothelial growth factor receptor 2 (VEGFR) expression in microarrays of patient EC tissue was examined in association with clinicopathological data. HER2 and VEGFR2 expression in Ishikawa cells and differences in migration and proliferation of cells with HER2-knockdown were evaluated. RESULTS: Higher expression of VEGFR2 was associated with lower International Federation of Obstetrics and Gynecology grades (p=0.044). The positive correlation between HER2 and VEFR2 expression was statistically significant in T1 stage (p=0.002) and International Federation of Obstetrics and Gynecology grade 1 tumors (p=0.004). Wound-healing assays revealed that HER2 loss in Ishikawa cells reduced confluence compared to that of control cells. CONCLUSION: The association of VEGFR2 and HER2 expression in early EC was elucidated. This study shows that the measurement of VEGFR2 expression may be useful in the preoperative assessment of EC and suggests the possibility of anti-HER2 therapy for EC. Copyright
Authors: David P Kodack; Euiheon Chung; Hiroshi Yamashita; Joao Incio; Annique M M J Duyverman; Youngchul Song; Christian T Farrar; Yuhui Huang; Eleanor Ager; Walid Kamoun; Shom Goel; Matija Snuderl; Alisha Lussiez; Lotte Hiddingh; Sidra Mahmood; Bakhos A Tannous; April F Eichler; Dai Fukumura; Jeffrey A Engelman; Rakesh K Jain Journal: Proc Natl Acad Sci U S A Date: 2012-10-15 Impact factor: 11.205
Authors: Gini F Fleming; Michael W Sill; Kathleen M Darcy; D Scott McMeekin; J Tate Thigpen; Lisa M Adler; Jonathan S Berek; Julia A Chapman; Paul A DiSilvestro; Ira R Horowitz; James V Fiorica Journal: Gynecol Oncol Date: 2009-10-18 Impact factor: 5.482
Authors: Herbert Hurwitz; Louis Fehrenbacher; William Novotny; Thomas Cartwright; John Hainsworth; William Heim; Jordan Berlin; Ari Baron; Susan Griffing; Eric Holmgren; Napoleone Ferrara; Gwen Fyfe; Beth Rogers; Robert Ross; Fairooz Kabbinavar Journal: N Engl J Med Date: 2004-06-03 Impact factor: 91.245